

## 1 **Biomarkers` performance in the SEPSIS-3 era**

2 Amanda de la Fuente<sup>1,2†</sup> (MSc), Jaime López-Sánchez<sup>3†</sup> (MD), Luis Mario Vaquero-Roncero<sup>2,4†</sup>  
3 (MD), María Merino García<sup>5</sup> (MD), María Elisa Sánchez Barrado<sup>2,4</sup> (MD), Miguel Vicente  
4 Sánchez-Hernández<sup>4</sup> (MD), Jesús Rico-Feijoo<sup>2,6</sup> (MD), Luis Muñoz-Bellvís<sup>3</sup> (MD), Rafael  
5 González de Castro<sup>5</sup> (MD), Ana P. Tedim<sup>1,2</sup> (PhD), Alicia Ortega<sup>1,2</sup> (MLT), Omar Abdel-lah  
6 Fernández<sup>3</sup> (MD), Alejandro Suárez-de-la-Rica<sup>8</sup> (MD), Emilio Maseda<sup>9</sup> (MD), Ignacio Trejo  
7 González<sup>4</sup> (MD), Geovanna Lizabeth García Carrera<sup>4</sup> (MD), José Miguel Marcos-Vidal<sup>5</sup> (MD),  
8 Juan Manuel Nieto Arranz<sup>3</sup> (MD), Carmen Esteban-Velasco<sup>3\*</sup> (MD), César Aldecoa<sup>2,5\*</sup> (MD),  
9 Jesús F Bermejo-Martin (MD)<sup>1, 2, 7\*</sup>

10 †These first authors contributed equally

11 \*These last authors contributed equally

12

13 1. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de  
14 Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-  
15 182, 37007 Salamanca, Spain.

16 2. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES,  
17 CB22/06/00035), Instituto de Salud Carlos III, Avenida de Monforte de Lemos, 3-5, 28029  
18 Madrid, Spain.

19 3. Department of General and Gastrointestinal Surgery, Hospital Universitario de Salamanca,  
20 Instituto de Investigación Biomédica de Salamanca (IBSAL) and Universidad de Salamanca,  
21 Salamanca, Spain.

22 4. Anaesthesiology and Reanimation Service, Complejo Asistencial Universitario de Salamanca,  
23 Salamanca, Spain.

24 5. Anaesthesiology and Reanimation Service, Complejo Asistencial Universitario de León, León,  
25 Spain.

26 6. Anaesthesiology and Reanimation Service, Hospital Universitario Río Hortega, Valladolid,  
27 Spain.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

28 7. School of Medicine, Universidad de Salamanca, C. Alfonso X el Sabio, s/n, 37007 Salamanca,  
29 Spain

30 8. Department of Anesthesiology and Surgical Critical Care, Hospital Universitario de La  
31 Princesa, 28006 Madrid, Spain.

32 9. Department of Anesthesiology and Surgical Critical Care, Hospital Universitario La Paz, 28046  
33 Madrid, Spain.

34

35 **Corresponding author:** Jesús F Bermejo-Martin, Group for Biomedical Research in  
36 Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL)  
37 Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007  
38 Salamanca, Spain, [jfbermejo@saludcastillayleon.es](mailto:jfbermejo@saludcastillayleon.es), +34 983 420 400 Ext: 168836.

39

40 **Abstract**

41 **Objective:** the biomarkers` performance for diagnosis and severity stratification of  
42 sepsis has not been properly evaluated anew using the SEPSIS-3 criteria introduced in  
43 2016. We evaluated the accuracy of 21 biomarkers classically tested in sepsis research to  
44 identify infection, sepsis, and septic shock in surgical patients classified using SEPSIS-3.

45 **Methods:** four groups of adult surgical patients were compared: post-surgical patients  
46 with no infection, patients with infection but no sepsis, patients with sepsis, and patients  
47 with septic shock were recruited prospectively from the surgery departments and surgical  
48 ICUs from four Spanish hospital. The area under the curve (AUC) to differentiate  
49 between groups was calculated for each biomarker.

50 **Results:** A total of 187 patients were recruited (50 uninfected post-surgery controls, 50  
51 patients with infection, 47 with sepsis and 40 with septic shock). The AUCs indicated  
52 that none of the biomarkers tested was accurate enough to differentiate those patients with  
53 infection from the uninfected controls. In contrast, procalcitonin, lipocalin 2, pentraxin 3,  
54 IL-15, TNF- $\alpha$ , IL-6, angiopoietin 2, TREM-1, D-dimer and C-reactive protein yielded  
55 AUCs  $\geq 0.80$  to discriminate the patients with sepsis or septic shock from those with no  
56 infection. C-reactive protein and IL-6 were the most accurate markers to differentiate  
57 plain infection from sepsis (AUC = 0.82). Finally, our results revealed that sepsis and  
58 septic shock shared similar profiles of biomarkers.

59 **Conclusion:** Reevaluation in the “SEPSIS-3 era” identified the scenarios where  
60 biomarkers do and do not provide useful information to improve the management of  
61 surgical patients with infection or sepsis.

62

63 **Keywords**

64 Biomarkers, Diagnosis, Sepsis, Severity

## 65 **Introduction**

66 Identification of sepsis remains a major challenge to implement prompt treatment in  
67 surgical patients suffering from this condition. Correct and quick discrimination between  
68 sepsis and surgical related inflammation allows to early implement measures aimed to  
69 control the infection source with surgery or antibiotics (1,2). Biomarkers are a potential  
70 useful tool to improve sepsis detection, complementary to clinical information and to  
71 image and/or microbiological tests, but the information regarding biomarkers must be  
72 provided in minutes in order to be useful (3,4) . In addition, the emergence of the SEPSIS-  
73 3 criteria in 2016 has re-shaped sepsis diagnosis, by proposing a new definition which  
74 consider sepsis just those infections causing life-threatening organ failure (5,6). While  
75 the introduction of the new SEPSIS-3 criteria has impacted epidemiological studies on  
76 sepsis (7–9), how SEPSIS-3 affects the performance of sepsis biomarkers has not been  
77 sufficiently studied yet.

78 In this work, we profiled a large number of biomarkers classically tested in sepsis studies  
79 by using a rapid microfluidics-based test, to evaluate their performance regarding  
80 identification of infection, sepsis and septic shock in surgical patients.

81

## 82 **Methods**

83 **Study design and patients:** Adult patients ( $\geq 18$  years) recruited in the first 24 hours  
84 following an abdominal surgery with no infection constituted the uninfected control  
85 group. Adult patients with infection, sepsis, or septic shock of abdominal source were  
86 recruited prospectively from the surgery departments and surgical intensive care units  
87 (ICUs) of the four participating hospitals (Hospital Universitario Río Hortega de  
88 Valladolid, Complejo Asistencial Universitario de Salamanca, Complejo Asistencial  
89 Universitario de León and Hospital Universitario Marqués de Valdecilla de Santander),

90 between January 2020 and July 2022. Infection was defined according to the US Centers  
91 for Disease Control and Prevention National Surveillance Definitions for Specific Types  
92 of Infections (10). Sepsis and septic shock were defined using the SEPSIS-3 consensus  
93 definitions (5,6). A specific standard survey was employed in the four participating  
94 hospitals to collect clinical data along with results of hematological, biochemical,  
95 radiological, and microbiological investigations. Healthy controls with similar age and  
96 sex characteristics to the patients were recruited from the Centro de Hemoterapia y  
97 Hemodonación de Castilla y León (CHEMCYL, Valladolid, Spain).

98 **Biomarkers profiling:** we quantified 20 biomarkers in plasma involved in different  
99 biological functions using the Ella-SimplePlex™ system from Biotechnne (San Jose,  
100 California, USA) as per manufacturer instructions. The biomarkers studied were the  
101 following: Lipocalin-2 (LCN2), Myeloperoxidase (MPO) (Neutrophil degranulation);  
102 Intercellular adhesion molecule 1 (ICAM-1), Vascular cell adhesion molecule 1  
103 (VCAM-1), Endothelin-1 (ET-1), Angiopoietin 2 (ANGPT2), Angiopoietin 1  
104 (ANGPT1) (Endothelial dysfunction); D-dimer, Urokinase-type plasminogen activator  
105 (uPA) (Coagulation); Interleukin 6 (IL-6), Interleukin 15 (IL-15), Tumoral necrosis  
106 factor  $\alpha$  (TNF- $\alpha$ ), Procalcitonin (PCT), Matrix metalloproteinase 7 (MMP7), Pentraxin  
107 3 (PTX3), TREM-1 (Inflammation); Interleukin 10 (IL-10), Programmed Death-ligand  
108 1 (PD-L1) (immunosuppression / immunomodulation), C-X-C motif chemokine ligand  
109 10 (CXCL10), Interleukin 7 (IL-7) (lymphocyte biology). Serum C-reactive protein  
110 (CRP) was measured by particle enhanced immunoturbidimetric assay (e501 Module  
111 Analyser, Roche Diagnostics, Meylan, France); limit of detection 0.15 mg/dL.

112 **Statistical analysis:** Statistical analysis was performed using IBM SPSS Statistics 25.0  
113 (SPSS INC, Armonk, NY, U.S.A). The level of significance was set at 0.05. For clinical  
114 characteristics of the patients, differences between groups were assessed using the  $\chi^2$  test

115 for categorical variables. Differences between groups for continuous variables and  
116 protein levels were assessed with the Kruskal–Wallis test. The accuracy of protein levels  
117 to differentiate between groups of patients was studied by calculating the area under the  
118 receiver operating characteristic curve (AUC). The optimal operating point (OOP) was  
119 calculated on the curve as previously described (11).

120

## 121 **Results**

122 Our study involved 187 patients, 50 uninfected post-surgery controls, 50 patients with  
123 infection without sepsis, 47 with sepsis and 40 with septic shock. Patients with infection  
124 were significantly younger than those in the other groups. Proportion of men to women  
125 were similar in all the compared groups. Patients with sepsis and septic shock had more  
126 frequently hypertension and chronic cardiac disease. Septic shock patients were the most  
127 severe as evidenced by their SOFA scores at admission and stayed longer at the hospital.  
128 None of the patients of the surgical control group or in the infection group died during  
129 hospitalization, compared with 7 out of 47 (14.9 %) patients with sepsis and 10 out of 40  
130 (25 %) patients with septic shock (Table S1, Supplementary material). The Kruskal-  
131 Wallis test evidenced that patients with sepsis and septic shock showed higher levels of  
132 PCT, LCN2, PTX3, IL-15, TNF- $\alpha$ , IL-6, ANGPT2, TREM-1, D-DIMER, CXCL10,  
133 VCAM-1, PD-L1 and MMP7 than healthy controls, surgical controls and patients with  
134 infection but no sepsis, being the levels of PCT, LCN2, PTX3 and IL-15 the highest in  
135 patients with septic shock (Fig 1; Table S2, Supplementary material).

136 We next calculated the AUCs for the different biomarkers to discriminate between  
137 uninfected post-surgery controls and the patients with infection, sepsis and septic shock  
138 (Fig 2; Table S3, Supplementary material). This analysis revealed that none of the  
139 biomarkers tested was accurate enough to differentiate patients with a plain infection from

140 post-surgery controls, yielding all AUCs < 0.80. In contrast, PCT, LCN2, PTX3, IL-15,  
141 TNF- $\alpha$ , IL-6, ANGPT2, TREM-1, D-DIMER and CRP yielded AUCs  $\geq$  0.80 to  
142 discriminate those patients with sepsis or septic shock from post-surgical patients with no  
143 infection (Fig 2; Table S3, Supplementary material). The corresponding OOP are shown  
144 Table S4 (Supplementary material). We also evaluated the biomarkers performance to  
145 stratify severity. This analysis revealed that CRP and IL-6 were good markers to  
146 differentiate plain infection from sepsis, yielding both AUCs of 0.82 for this comparison  
147 (Table S3, Supplementary material). The corresponding OOP are shown Table S4  
148 (Supplementary material). In turn, PCT, LCN2, PTX3, IL-15, TNF- $\alpha$ , IL-6, ANGPT2,  
149 CRP and IL-10 showed all AUCs  $\geq$  0.80 to discriminate between infection and septic  
150 shock (Table S3, Supplementary material). The corresponding OOP are shown Table S4  
151 (Supplementary material). Finally, our results revealed that sepsis and septic shock shared  
152 similar profiles of biomarkers, with none of them yielding AUCs  $\geq$  0.80 to differentiate  
153 between these two conditions (Table S3, Supplementary material).

154

## 155 **Discussion**

156 Since the introduction of the new SEPSIS-3 criteria in 2016, studies evaluating the  
157 performance of biomarkers to diagnose and to stratify sepsis severity are lacking or  
158 focused on a limited number of molecules (12–16). Here we evaluated 21 biomarkers  
159 involved in different biological functions in sepsis (inflammation, neutrophil  
160 degranulation, endothelial dysfunction, coagulation, immunosuppression and lymphocyte  
161 biology), and compared their performance to discriminate between surgical patients with  
162 no infection, infection with no sepsis, sepsis or septic shock, as defined by SEPSIS-3. Our  
163 results evidenced the limitations of the assessed biomarkers to differentiate those patients  
164 with infection from those with no infection, revealing that, in absence of significant organ

165 failure, the biological response to an infectious or to a surgical challenge is similar. While  
166 these results evidence that the biomarkers tested would not be helpful to better allocate  
167 antibiotic treatment in patients with suspected infection when sepsis is absent, we  
168 identified in contrast a number of them (PCT, LCN2, PTX3, IL-15, TNF- $\alpha$ , IL-6,  
169 ANGPT2, TREM-1, D-DIMER, CRP) which definitively could contribute to quickly  
170 identify those patients with sepsis or septic shock and to early implement empiric therapy  
171 with wide spectrum antibiotics, along with the other bundles recommended by the  
172 surviving sepsis campaign (hemodynamic management, ICU admission, antimicrobial  
173 therapy, implementation of any required source control intervention, ventilation and other  
174 additional therapies) (17). In turn, CRP and IL-6 were also good candidates to  
175 differentiate surgical patients with infection with or without sepsis. This finding is also  
176 very important from a translational point of view since quantification of these biomarkers  
177 is widely available in hospital settings. Finally, our study revealed that none of the  
178 biomarkers evaluated was good enough to differentiate between patients with sepsis and  
179 those with septic shock, revealing that both scenarios induce similar alterations in the host  
180 response.

181 A strength of our study is that we employed a next-generation immunoassay based on  
182 microfluidics (Ella-SimplePlex) which provides biomarkers levels in less than 90  
183 minutes, which is a reasonable frame time to provide actionable information in patients  
184 with suspected sepsis or septic shock. While the limited sample size makes this a pilot  
185 study, our results warrant further evaluation of biomarker profiling using Ella-SimplePlex  
186 in larger cohorts of patients.

187 In conclusion, our study re-approached the performance of sepsis biomarkers in the  
188 “SEPSIS-3 era”, identifying the scenarios and molecules really adding valuable

189 information to improve the management of surgical patients suffering this deadly

190 condition.

191

192 **List of abbreviations**

193 ANGPT2: Angiopoietin 2

194 AUC: Area under the receiver operating characteristic curve

195 CXCL10: C-X-C motif chemokine ligand 10

196 ICAM-1: Intercellular adhesion molecule 1

197 ICU: Intensive care unit

198 IL-6: Interleukin 6

199 IL-7: Interleukin 7

200 IL-10: Interleukin 10

201 IL-15: Interleukin 15

202 MMP7: Matrix metalloproteinase 7

203 OOP: Optimal operating point

204 PD-L1: Programmed Death-ligand 1

205 PCT: Procalcitonin

206 SOFA: Sepsis related Organ Failure Assessment

207 TNF- $\alpha$ : Tumor necrosis factor  $\alpha$

208 TREM-1: Triggering receptor expressed on myeloid cells 1

209 uPA: Urokinase-type plasminogen activator

210 VCAM-1: Vascular cell adhesion molecule 1

211

212 **Ethics approval and consent to participate:** The study was approved by the respective  
213 Committees for Ethics in Clinical Research of the three participating hospitals. Methods  
214 were carried out in accordance with current Spanish law for Biomedical Research,  
215 fulfilling the standards indicated by the Declaration of Helsinki. The study was approved  
216 by the Committee for Ethical Research of the coordinating institution, “Comite de Etica

217 de la Investigacion con Medicamentos del Área de Salud de Valladolid Oeste”, code  
218 PI142-19. Written informed consent was obtained from patients' relatives or their legal  
219 representative before enrolment.

220 **Consent for publication:** not applicable

221 **Availability of data and materials:** The datasets generated and/or analysed during the  
222 current study are not publicly available since they are still under elaboration for  
223 publication by the authors but are available from the corresponding author on reasonable  
224 request.

225 **Competing interests:** The authors declare that they have no competing interests

226 **Funding:** This study has been funded by Instituto de Salud Carlos III (ISCIII) and co-  
227 funded by the European Union: Project “PI19/00590” (JFBM), Sara Borrell  
228 program “CD018/0123” (APT) and PFIS program “FI20/00278” (AdF). The funding  
229 sources did not play any role in the design of the study and collection, analysis,  
230 interpretation of data or writing the manuscript.

231 **Authors' contributions:** JFBM designed the study. AdIF, JL, LMVR, MMG, MESB,  
232 MVSH, JMMV, JRF, LMB, RGdC, APT, AO, ASdR, EM, CEV and CA contributed with  
233 patient recruitment and data acquisition. AdIF and AO profiled biomarker levels in  
234 plasma. JFBM and AdIF analyzed and interpreted of data and drafted the manuscript.  
235 All the authors critically reviewed the article and provided final approval of the version  
236 submitted for publication.

237 **Acknowledgements:** The authors thank the nursing teams of the participating clinical  
238 services for their continuous support to the research programme. They also thank the  
239 Biobanco Hospital Clínico Universitario de Salamanca, for assistance with sample  
240 storing, and CHEMCYL (Valladolid, Spain) for providing the samples from healthy  
241 controls.

## 242 **References**


- 243 1. Brakenridge SC, Chen UI, Loftus T, Ungaro R, Dirain M, Kerr A, et al. Evaluation of a  
244 Multivalent Transcriptomic Metric for Diagnosing Surgical Sepsis and Estimating Mortality  
245 Among Critically Ill Patients. *JAMA Netw Open*. 2022 Jul 12;5(7):e2221520.
- 246 2. Jeong YK, Kim EY. Predictive Role of Changes in Presepsin and Early Sepsis in ICU Patients  
247 After Abdominal Surgery. *J Surg Res*. 2022 Oct 1;278:207–15.
- 248 3. Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent JL. Biomarkers of sepsis: time  
249 for a reappraisal. *Crit Care*. 2020 Jun 5;24(1):287.
- 250 4. Barichello T, Generoso JS, Singer M, Dal-Pizzol F. Biomarkers for sepsis: more than just  
251 fever and leukocytosis—a narrative review. *Crit Care*. 2022 Dec;26(1):14.
- 252 5. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The  
253 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*.  
254 2016 Feb 23;315(8):801–10.
- 255 6. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al.  
256 Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the  
257 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*.  
258 2016 Feb 23;315(8):775–87.
- 259 7. Vermassen J, Decruyenaere J, De Bus L, Depuydt P, Colpaert K. Characteristics of Sepsis-2  
260 septic shock patients failing to satisfy the Sepsis-3 septic shock definition: an analysis of real-  
261 time collected data. *Ann Intensive Care*. 2021 Oct 30;11(1):154.
- 262 8. Engoren M, Seelhammer T, Freundlich RE, Maile MD, Sigakis MJG, Schwann TA. A  
263 Comparison of Sepsis-2 (Systemic Inflammatory Response Syndrome Based) to Sepsis-3  
264 (Sequential Organ Failure Assessment Based) Definitions—A Multicenter Retrospective  
265 Study\*. *Crit Care Med*. 2020 Sep;48(9):1258.

- 266 9. Williams JM, Greenslade JH, McKenzie JV, Chu K, Brown AFT, Lipman J. Systemic  
267 Inflammatory Response Syndrome, Quick Sequential Organ Function Assessment, and  
268 Organ Dysfunction: Insights From a Prospective Database of ED Patients With Infection.  
269 CHEST. 2017 Mar 1;151(3):586–96.
- 270 10. Centers for Disease Control and Prevention. CDC/NHSN Surveillance Definitions for  
271 Specific Types of Infections; updated 2014 [Internet]. 2022. Available from:  
272 [https://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef\\_current.pdf](https://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf)
- 273 11. Almansa R, Ortega A, Ávila-Alonso A, Heredia-Rodríguez M, Martín S, Benavides D, et al.  
274 Quantification of Immune Dysregulation by Next-generation Polymerase Chain Reaction to  
275 Improve Sepsis Diagnosis in Surgical Patients. *Ann Surg*. 2019 Mar;269(3):545–53.
- 276 12. Song J, Park DW, Moon S, Cho HJ, Park JH, Seok H, et al. Diagnostic and prognostic value  
277 of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients:  
278 a prospective controlled study according to the Sepsis-3 definitions. *BMC Infect Dis*. 2019  
279 Nov 12;19(1):968.
- 280 13. Song J, Moon S, Park DW, Cho HJ, Kim JY, Park J, et al. Biomarker combination and SOFA  
281 score for the prediction of mortality in sepsis and septic shock: A prospective observational  
282 study according to the Sepsis-3 definitions. *Medicine (Baltimore)*. 2020 May  
283 29;99(22):e20495.
- 284 14. Huang N, Chen J, Wei Y, Liu Y, Yuan K, Chen J, et al. Multi-marker approach using C-  
285 reactive protein, procalcitonin, neutrophil CD64 index for the prognosis of sepsis in intensive  
286 care unit: a retrospective cohort study. *BMC Infect Dis*. 2022 Jul 30;22(1):662.
- 287 15. Lee S, Song J, Park DW, Seok H, Ahn S, Kim J, et al. Diagnostic and prognostic value of  
288 presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock: a  
289 prospective observational study according to the Sepsis-3 definitions. *BMC Infect Dis*. 2022  
290 Jan 4;22(1):8.

- 291 16. Xie Y, Zhuang D, Chen H, Zou S, Chen W, Chen Y. 28-day sepsis mortality prediction model  
292 from combined serial interleukin-6, lactate, and procalcitonin measurements: a retrospective  
293 cohort study. *Eur J Clin Microbiol Infect Dis*. 2023 Jan 1;42(1):77–85.
- 294 17. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving  
295 Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock  
296 2021. *Crit Care Med*. 2021 Nov;49(11):e1063.
- 297

298 **Tables and figures**

299 **Figure 1. Levels of biomarkers in healthy control, surgical control, infection, sepsis**  
300 **and septic shock groups.** Levels are in pg/mL. ET, endothelin; IL, Interleukin; CRP, C  
301 reactive protein; PD-L1, programmed death-ligand 1; TNF, tumor necrosis factor;  
302 ANGPT, angiopoietin; CXCL, chemokine ligand; MMP, matrix metalloproteinase; PCT,  
303 procalcitonin, TREM, triggering receptor expressed on myeloid cells-1; uPA, urokinase-  
304 type plasminogen activator; ICAM, intercellular adhesion molecule; VCAM, vascular  
305 cell adhesion molecule; PTX, pentraxin; LCN, lipocalin; MPO, myeloperoxidase. \* $P \leq$   
306 0.050 *versus* healthy control; †  $P \leq 0.050$  (Kruskal – Wallis test).



307

308

309

310 **Figure 2. “Big Bang” Plot. AUC to differentiate patients with infection, sepsis, and**  
 311 **septic shock from surgical controls.** ET, endothelin; IL, Interleukin; CRP, C reactive  
 312 protein; PD-L1, programmed death-ligand 1; TNF, tumor necrosis factor; ANGPT,  
 313 angiotensin; CXCL, chemokine ligand; MMP, matrix metalloproteinase; PCT,  
 314 procalcitonin, TREM, triggering receptor expressed on myeloid cells-1; uPA,  
 315 urokinase-type plasminogen activator; ICAM, intercellular adhesion molecule; VCAM,  
 316 vascular cell adhesion molecule; PTX, pentraxin; LCN, lipocalin; MPO,  
 317 myeloperoxidase.

